I’ve been asked by clients and friends to share the information my team and I are constantly monitoring on the CBD industry, and while I don’t expect to catch everything, we are in the middle of trying to organize the massive amounts of information that has become all too routine in mass media about the cannabis industry.
This is the first in what I expect will be a series of “Weekly Review” pieces, chronicling CBD market news and, as appropriate, news on related scientific, political, and regulatory matters.
By calendrical good fortune, I can inaugurate this series with the midterm elections in the United States. But let me start with this week’s most notable:
Steady Stomach - CBD and Irritable Bowel Syndrome
We will begin this CBD industry summary, though, with an item that is not (directly) related to the election, and that in fact comes from north of the US border. SciCann Therapeutics, of Toronto, announced on November 6 that it has received good news on a “prior art” search pursuant to its patent application for a CBD Combination Therapy.
The therapy in question is known as “Steady Stomach,” a proprietary combination that includes CBD and that is intended for the treatment of patients with irritable bowel syndrome.
In the development of Steady Stomach, SciCann, a specialty pharm concern active in oncology, pain management, neurodegenerative diseases and inflammatory disorders, has partnered with FSD Pharma, a cannabis producer with a property in Cobourg, Ontario that the company hopes to transform into the largest hydroponic indoor grow facility in the world.
The FSD/SciCann partnership claims that in tests on mice the proprietary combination has shown a three-fold increased efficacy in lowering abdominal inflammation levels as compared to CBD alone.
On October 31, the FSD/SciCann partnership launched a clinical study of the safety and efficacy of Steady Stomach in humans.
On November 6, the partnership announced a positive search report with regard to prior work -- a finding at least as a preliminary matter that the combination at issue is novel. They will proceed with the patent process.
To me, it indicates that both the science and the commerce of applications of CBD are chugging along in a now-routine way, which should itself inform the decisions of voters in the US. Why? Because Cannabis has become a mainstream conversation, a routine part of America’s news cycle; therefore this midterm’s elections results should matter to anyone interested how their health will be affected by this pioneering industry.